Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


A randomised, placebo controlled trial of psilocybin in treatment resistant depression: A feasibility study


To see complete record on www.clinicaltrialsregister.eu, please visit this link

Id: 2018-003573-97

Organisation Name: South London & Maudsley NHS Foundation Trust

Start Date: 2020-08-27

Completion Date: Ongoing

Brief Summary: To evaluate the feasibility of a randomised, controlled trial design, in which a single dose of psilocybin 25mg PO vs placebo, is given to adult participants with treatment resistant major depressive disorder (TRD), under psychologically supportive conditions, with 6 weeks of follow up, by measuring recruitment rates, dropout rates and by estimating the variance of the primary outcome measure (MADRS) to inform upon the design of a phase 3 trial.

Country: United Kingdom



Total execution time in seconds: 0.049817085266113